Zealand Pharma A/S outlined its strategy for redefining weight management and establishing leadership in metabolic health during its Capital Markets Day in London. By 2030, the company aims to launch five products supported by a robust clinical pipeline of over ten programs. Zealand Pharma plans to leverage its peptide expertise, organizational structure, and global research capabilities to achieve industry-leading cycle times from idea to clinic. Through advanced computational methods and collaborations, the company will accelerate drug discovery and expand its molecule-making toolbox, positioning itself as a leader in metabolic health.

Read more at Nasdaq: Zealand Pharma Unveils Strategy To Lead In Metabolic Health